Business Context and Reporting Period
This Form 8-K Current Report was filed by NextCure, Inc. on September 14, 2020, covering events that occurred on September 10, 2020. The filing addresses changes to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Resignation: Judith J. Li resigned from the Board of Directors effective September 10, 2020. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: John G. Houston, Ph.D., was appointed to the Board to fill the vacancy created by Ms. Li's resignation. He serves as a Class I director until the 2023 annual meeting.
- Committee Assignment: Dr. Houston was appointed to the Nominating and Corporate Governance Committee.
Management Commentary and Risks
Management highlighted Dr. Houston's extensive background, including his role as President and CEO of Arvinas, Inc., and over 18 years of experience at Bristol Myers Squibb Company. The Company entered into a customary indemnification agreement with Dr. Houston and will compensate him under the Non-Employee Director Compensation Program. No specific risks or contingencies related to financial performance were disclosed in this filing.
Key Facts for Investor Verification
- Verify the effective date of Judith J. Li's resignation (September 10, 2020).
- Confirm John G. Houston's tenure as a Class I director until the 2023 annual meeting.
- Review the attached Non-Employee Director Compensation Program (Exhibit 10.1) for details on Dr. Houston's compensation.
- Note that this filing contains no financial results; investors should refer to recent 10-Q or 10-K filings for financial metrics.